Novartis AG ADR (NVS)vsOraSure Technologies Inc (OSUR)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
OSUR
OraSure Technologies Inc
$3.04
+2.70%
HEALTHCARE · Cap: $208.07M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 49089% more annual revenue ($56.58B vs $115.02M). NVS leads profitability with a 23.9% profit margin vs -59.8%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OSUR
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+60.5%
Fair Value
$7.14
Current Price
$3.04
$4.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 29.6% YoY
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -18.3% — below average capital efficiency
Revenue declined 28.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OSUR
The strongest argument for OSUR centers on Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : OSUR
The primary concerns for OSUR are Market Cap, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while OSUR is a turnaround play — different risk/reward profiles.
OSUR carries more volatility with a beta of 0.85 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 42/100), backed by strong 23.9% margins. OSUR offers better value entry with a 60.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →OraSure Technologies Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and sample collection devices in the United States, Europe, and internationally. The company is headquartered in Bethlehem, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?